W. Dalton Dietrich
7
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 7 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Autologous Human Schwann Cells in Peripheral Nerve Repair
Role: lead
Safety and Efficacy of Autologous Human Schwann Cell (ahSC) Augmentation in Severe Peripheral Nerve Injury (PNI)
Role: lead
Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Role: lead
Expanded Access - Autologous Human Schwann Cells in Peripheral Nerve Repair
Role: lead
The Safety of ahSC in Chronic SCI With Rehabilitation
Role: lead
Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair
Role: lead
Safety of Autologous Human Schwann Cells (ahSC) in Subjects With Subacute SCI
Role: lead
All 7 trials loaded